Weekly Digest – September 2026 Weekly Digest – September 2026 08 September 2026: Adlai Nortye announced the first patient dosing in Australia and U.S. FDA IND clearance for AN4035 Adlai Nortye announced that the first patient has been dosed in […]
Weekly Digest – September 2026 Weekly Digest – September 2026 08 September 2026: Adlai Nortye announced the first patient dosing in Australia and U.S. FDA IND clearance for AN4035 Adlai Nortye announced that the first patient has been dosed in […]
Weekly Digest – September 2026 Weekly Digest – September 2026 04 September 2026: Acepodia announces FDA clearance of IND application for ACE723, a novel dual-payload ADC Acepodia announced that the U.S. FDA has cleared the IND application for ACE723, a […]
Weekly Digest – September 2026 Weekly Digest – September 2026 09 September 2026: InnoCare announced approval in China to initiate clinical trials of ICP-B381, a novel PSMA/STEAP1-targeting bispecific ADC InnoCare Pharma announced that China’s NMPA has approved the clinical trial […]
Weekly Digest – September 2026 Weekly Digest – September 2026 09 September 2026: Adagene announced a milestone with Exelixis supporting the advancement of SAFEbody ADC candidates Adagene announced that it has achieved a milestone under its collaboration and license agreement […]
Weekly Digest – September 2026 Weekly Digest – September 2026 08 September 2026: Cellbion and AHN-GOOK Pharmaceutical announced a collaboration for the joint development of next-generation radiopharmaceuticals Cellbion and AHN-GOOK Pharmaceutical announced a memorandum of understanding to jointly research and […]
Weekly Digest – September 2026 Weekly Digest – September 2026 08 September 2026: ITM and SpiroChem announced a strategic discovery collaboration to expand ITM’s radiopharmaceutical pipeline ITM Isotope Technologies Munich and SpiroChem announced a strategic drug discovery collaboration to advance […]
Weekly Digest – September 2026 Weekly Digest – September 2026 03 September 2026: HUTCHMED announces licensing agreement with GSK for KRAS-EGFR antibody conjugate cancer therapy HUTCHMED announced an exclusive licensing agreement with GSK for HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy […]
Weekly Digest – September 2026 Weekly Digest – September 2026 01 September 2026: SYS6010 granted BTD by the NMPA in China for the treatment of patients with recurrent or metastatic HNSCC CSPC Pharmaceutical Group announced that SYS6010 has received Breakthrough […]
Weekly Digest – September 2026 Weekly Digest – September 2026 02 September 2026: Hansoh Pharmaceutical’s HS-20093 injection marketing authorization application for SCLC accepted by China’s NMPA Hansoh Pharma announced that the NMPA has formally accepted the marketing authorization application for […]
Weekly Digest – September 2026 Weekly Digest – September 2026 31 August 2026: IDEAYA Biosciences’ IDE849 advances to a phase 3 registrational trial following a successful FDA type C meeting for ES-SCLC IDEAYA Biosciences announced a successful FDA Type C […]
info@ciscientists.com
For a subscription, please provide your email id